Latest news with #GraceTherapeutics
Yahoo
25-05-2025
- Business
- Yahoo
This Grace Therapeutics Insider Increased Their Holding By 12% Last Year
Insiders were net buyers of Grace Therapeutics, Inc.'s (NASDAQ:GRCE ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. In the last twelve months, the biggest single purchase by an insider was when Independent Chairman Vimal Kavuru bought US$500k worth of shares at a price of US$3.40 per share. That means that an insider was happy to buy shares at above the current price of US$2.97. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Vimal Kavuru was the only individual insider to buy during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! Check out our latest analysis for Grace Therapeutics There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. Grace Therapeutics insiders own about US$7.6m worth of shares. That equates to 19% of the company. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment. There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. Overall we don't see anything to make us think Grace Therapeutics insiders are doubting the company, and they do own shares. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To that end, you should learn about the 3 warning signs we've spotted with Grace Therapeutics (including 2 which are significant). Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Globe and Mail
02-05-2025
- Business
- Globe and Mail
Biotech Stock Ends Week On High Note Following Bullish Coverage Initiation
A New Jersey-based biotech found success to finish out the week after it was announced that TD Cowen initiated coverage on the company with a buy rating and a price target of $12. Seeing that this micro cap closed yesterday at just $2.71, it's now wonder traders rushed in. So far this session, the buying pressure was enough to get shares of Grace Therapeutics Inc. (Nasdaq:GRCE) up to $2.8604/share (+5.55%) at the early session high. This move is a strong continuation of the success this stock has had so far this month. Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
Yahoo
10-02-2025
- Business
- Yahoo
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
On Monday, Grace Therapeutics, Inc. (NASDAQ:GRCE), formerly b, announced topline data from its Phase 3 STRIVE-ON safety trial of GTx-104 compared with oral nimodipine in patients hospitalized with aneurysmal Subarachnoid Hemorrhage (aSAH). aSAH is bleeding over the brain's surface in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. The study met its primary endpoint and provides evidence of clinical benefit compared to orally administered nimodipine. The trial met its primary endpoint, with patients receiving GTx-104 observed to have a 19% reduction in at least one incidence of clinically significant hypotension compared to oral nimodipine (28% versus 35%). Other measures also favored or were comparable to GTx-104, including: 54% of patients who received GTx-104 had a relative dose intensity (RDI) of 95% or higher of the prescribed dose compared to only 8% on oral nimodipine. 29% relative increase in the number of patients receiving GTx-104 compared to oral nimodipine with favorable outcomes at 90 days follow-up on the modified Rankin scale. Fewer intensive care unit (ICU) readmissions, ICU days, and ventilator days for patients receiving GTx-104 versus oral nimodipine. Adverse events were comparable between the two arms and no new safety issues were identified with patients receiving GTx-104. All deaths in both arms of the trial were due to the severity of the patient's underlying disease. US new drug application submission is expected in the first half of 2025. Concurrently, Grace Therapeutics announced a private placement of approximately $30 million consisting of initial upfront funding of approximately $15.0 million and the potential to receive up to an additional approximately $15.0 million upon cash exercise of accompanying warrants at the election of the investors. Grace Therapeutics will issue an aggregate of 4.42 million common shares and accompanying common warrants to purchase up to 4.42 million at a combined purchase price of $3.395. Grace Therapeutics will use the net proceeds to fund the development of GTx-104. Price Action: GRCE stock is up 4.32% at $3.38 at last check Monday. Read Next:UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
